120 related articles for article (PubMed ID: 37918013)
1. Multivariate Prognostic Models for Patients with Stages I and Ii Colon Carcinoma: a Strobe-Compliant Retrospective Cohort Study.
Oñate-Ocaña LF; Herrera-Goepfert R; Avilés-Salas A; Cortés CC; González-Trejo S; Carrillo JF; Ruiz-García E; Ochoa-Carrillo FJ; Aiello-Crocifoglio V; García-Cuellar CM
Rev Invest Clin; 2023; 75(5):259-271. PubMed ID: 37918013
[TBL] [Abstract][Full Text] [Related]
2. Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic Factor for Recurrence and Survival After Curative Resection Followed by Adjuvant Chemotherapy in Stage III Colon Cancer.
Kim CG; Ahn JB; Jung M; Beom SH; Heo SJ; Kim JH; Kim YJ; Kim NK; Min BS; Koom WS; Kim H; Roh YH; Ma BG; Shin SJ
Ann Surg Oncol; 2017 Jan; 24(1):227-235. PubMed ID: 27699609
[TBL] [Abstract][Full Text] [Related]
3. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
Dalerba P; Sahoo D; Paik S; Guo X; Yothers G; Song N; Wilcox-Fogel N; Forgó E; Rajendran PS; Miranda SP; Hisamori S; Hutchison J; Kalisky T; Qian D; Wolmark N; Fisher GA; van de Rijn M; Clarke MF
N Engl J Med; 2016 Jan; 374(3):211-22. PubMed ID: 26789870
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic value and initial exploratory research on TNM staging method of tumor deposits in stage III colon cancer].
Qin Q; Yang L; Zhou AP; Wang JW; Zhong DS
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Dec; 22(12):1152-1158. PubMed ID: 31874531
[No Abstract] [Full Text] [Related]
5. Prognostic impact of primary tumor location in Stage III colorectal cancer-right-sided colon versus left-sided colon versus rectum: a nationwide multicenter retrospective study.
Shida D; Inoue M; Tanabe T; Moritani K; Tsukamoto S; Yamauchi S; Sugihara K; Kanemitsu Y
J Gastroenterol; 2020 Oct; 55(10):958-968. PubMed ID: 32651860
[TBL] [Abstract][Full Text] [Related]
6. The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trials.
Cascinu S; Poli D; Zaniboni A; Lonardi S; Labianca R; Sobrero A; Rosati G; Di Bartolomeo M; Scartozzi M; Zagonel V; Pella N; Banzi M; Torri V
Eur J Cancer; 2019 Apr; 111():1-7. PubMed ID: 30797014
[TBL] [Abstract][Full Text] [Related]
7. Microsatellite Instability as a Prognostic Factor in Stage II Colon Cancer Patients, a Meta-Analysis of Published Literature.
Gkekas I; Novotny J; Pecen L; Strigård K; Palmqvist R; Gunnarsson U
Anticancer Res; 2017 Dec; 37(12):6563-6574. PubMed ID: 29187431
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.
Zhang JX; Song W; Chen ZH; Wei JH; Liao YJ; Lei J; Hu M; Chen GZ; Liao B; Lu J; Zhao HW; Chen W; He YL; Wang HY; Xie D; Luo JH
Lancet Oncol; 2013 Dec; 14(13):1295-306. PubMed ID: 24239208
[TBL] [Abstract][Full Text] [Related]
9. Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status.
Taieb J; Kourie HR; Emile JF; Le Malicot K; Balogoun R; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Mulot C; Bouché O; Aparicio T; Michel P; Thaler J; Bridgewater J; Van Cutsem E; Perkins G; Lepage C; Salazar R; Laurent-Puig P;
JAMA Oncol; 2018 Jul; 4(7):e173695. PubMed ID: 29167892
[TBL] [Abstract][Full Text] [Related]
10. Risk of recurrence in patients with colon cancer stage II and III: a systematic review and meta-analysis of recent literature.
Böckelman C; Engelmann BE; Kaprio T; Hansen TF; Glimelius B
Acta Oncol; 2015 Jan; 54(1):5-16. PubMed ID: 25430983
[TBL] [Abstract][Full Text] [Related]
11. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
Sinicrope FA; Foster NR; Thibodeau SN; Marsoni S; Monges G; Labianca R; Kim GP; Yothers G; Allegra C; Moore MJ; Gallinger S; Sargent DJ
J Natl Cancer Inst; 2011 Jun; 103(11):863-75. PubMed ID: 21597022
[TBL] [Abstract][Full Text] [Related]
12. Utilization and impact of adjuvant chemotherapy among patients with resected stage II colon cancer: a multi-institutional analysis.
Ejaz A; Casadaban L; Maker AV
J Surg Res; 2017 Jul; 215():12-20. PubMed ID: 28688636
[TBL] [Abstract][Full Text] [Related]
13. Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy.
Kim JE; Hong YS; Kim HJ; Kim KP; Lee JL; Park SJ; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Hoon KJ; Kim TW
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S630-7. PubMed ID: 26271397
[TBL] [Abstract][Full Text] [Related]
14. Neutrophils to lymphocytes ratio as a useful prognosticator for stage II colorectal cancer patients.
Dimitriou N; Felekouras E; Karavokyros I; Alexandrou A; Pikoulis E; Griniatsos J
BMC Cancer; 2018 Dec; 18(1):1202. PubMed ID: 30509242
[TBL] [Abstract][Full Text] [Related]
15. Identification of patients with high-risk stage II colon cancer for adjuvant therapy.
Quah HM; Chou JF; Gonen M; Shia J; Schrag D; Landmann RG; Guillem JG; Paty PB; Temple LK; Wong WD; Weiser MR
Dis Colon Rectum; 2008 May; 51(5):503-7. PubMed ID: 18322753
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and predictive roles of DNA mismatch repair status in colon cancer patients treated with oxaliplatin-based chemotherapy: a retrospective study.
Qin Q; Zhou AP; Yang L; Xu C; Sun YK; Zhang W; Wang JW; Zhong DS
J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33316771
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer.
Kumar A; Kennecke HF; Renouf DJ; Lim HJ; Gill S; Woods R; Speers C; Cheung WY
Cancer; 2015 Feb; 121(4):527-34. PubMed ID: 25332117
[TBL] [Abstract][Full Text] [Related]
18. Quantitative analysis of CDX2 protein expression improves its clinical utility as a prognostic biomarker in stage II and III colon cancer.
den Uil SH; de Wit M; Slebos RJC; Delis-van Diemen PM; Sanders J; Piersma SR; Pham TV; Coupé VMH; Bril H; Stockmann HBAC; Jimenez CR; Meijer GA; Fijneman RJA
Eur J Cancer; 2021 Feb; 144():91-100. PubMed ID: 33341450
[TBL] [Abstract][Full Text] [Related]
19. Peripheral Neutrophil to Lymphocyte Ratio Improves Prognostication in Colon Cancer.
Rashtak S; Ruan X; Druliner BR; Liu H; Therneau T; Mouchli M; Boardman LA
Clin Colorectal Cancer; 2017 Jun; 16(2):115-123.e3. PubMed ID: 28365393
[TBL] [Abstract][Full Text] [Related]
20. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
